This question has three parts, make sure to answer ALL quest…
This question has three parts, make sure to answer ALL questions in the answer box. Part I: Below is a list of effectors for epigenetic editing. Effectors are genes that encodes proteins that could change epigenetic status of histone or DNA or RNA P300: histone lysine acetyltransferase, add acetyl group to histone lysine CBP: histone lysine acetyltransferase, add acetyl group to histone lysine EZH2: catalytic component of the PRC2 complex, adding methylation to H3K27 KMT: histone lysine methyltransferase, responsible for H3K4 methylation DNMT1A: DNA methyltransferase, activate during mitosis DNMT3A: de novo methyltransferase TET: demethylate DNA HDAC1: histone deacetylase, remove acetylation from histone tails KRAB: H3K9 histone methyltransferase leadings to H3K9me3 PHF8: remove histone methyl group from H3K9 1. list all effectors you think it will leads to gene activation, you can use the letter that matches the effectors. 3′ 2. A researcher wants to silence a oncogene in cancer cells using a dCas9-based epigenome editing system. They design a construct using the KAL (dCas9–p300 core domain) system. Apply your knowledge to explain how this system achieves what you want. 3′ Part II: Targeting P16 for cancer therapy P16 is a tumor suppressor gene that involved in cell cycle control. It also prevents cells from cell death and inhibits vascular growth. P16 is silenced in almost 50% of cancers (including liver, biliary tract, lung, bladder and esophagus cancer). However, overexpression of P16 has also found in some pre-malignant tumors but not in high stage tumor. 3. Using what you learnt from the lecture, assuming you are treating hepatocarcinoma (liver cancer) stage 4 patients. do you think you should design a epigenetic editing tool to increase or decrease the gene expression of P16? Pick up three effectors from the list and tell me WHY you pick up these three effectors. 4′ 4. What system (Cas 9 or dCas 9 or DBDs) you will use to ONLY modulate P16 location (specificity)? what is the function of gRNA in this system? If you want to use a silence that gene only after the cells is differentiated, how you could achieve that?5′
Read DetailsLook at the exam handout. Assume the same setup as Question…
Look at the exam handout. Assume the same setup as Question 14 above – Huron Corp buys Superior Corp at a 25% premium in a 50% cash / 50% stock deal (i.e., 50% of the consideration to the Superior Corp shareholders would be in cash and 50% of the consideration would be in shares of the Pro Forma Entity) on 12/31/2026. What percentage of the Pro Forma entity would Superior Corp shareholders own? If Huron is listed on the NYSE, would this require a shareholder vote of Huron (i.e., the acquirer’s shareholders)?
Read DetailsLook at the exam handout. Assume Erie Corp buys Superior Cor…
Look at the exam handout. Assume Erie Corp buys Superior Corp for a 30% premium in an all-cash deal. What amount of revenue synergies would be required so that the annual revenue growth rate in CY 2029 for the Pro Forma Entity is 2.0% higher than Erie Corp’s standalone annual revenue growth rate in CY 2029? Assume the revenue synergies are phased in 25% in 2026, 50% in 2027 and 100% in 2028 and a transaction closing date of 12/31/2025. Round your answer to the nearest $25 dollars.
Read Details